ERBB2 and breast cancer: Therefore, in addition to the established prognostic markers (e.g., p-STAT3, HER2 and LDH) have of breast cancer (7–9), immunologically favorable biomarkers are also needed to guide the choice and administration of therapeutic strategy for breast cancer patients.